- Home
- TONX vs FATE Comparison
TONX vs FATE Comparison
Compare TONX & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TONX | FATE |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | 23 | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.5M | 125.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | TONX | FATE |
|---|---|---|
| Price | $2.66 | $1.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | 361.6K | ★ 1.5M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | $526.82 | N/A |
| Revenue Next Year | $45.45 | N/A |
| P/E Ratio | $0.26 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.75 | $0.66 |
| 52 Week High | $8.23 | $1.94 |
Technical Indicators
Market Signals| Indicator | TONX | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 50.20 | 42.07 |
| Support Level | $1.80 | $0.96 |
| Resistance Level | $3.61 | $1.14 |
| Average True Range (ATR) | 0.29 | 0.09 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 23.66 | 23.08 |
Price Performance
Historical ComparisonAbout TONX TON Strategy Company
TON Strategy Co is a leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The company's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.